These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 15720781)

  • 41. Integrated pharmacokinetics and pharmacodynamics in drug development.
    Dingemanse J; Appel-Dingemanse S
    Clin Pharmacokinet; 2007; 46(9):713-37. PubMed ID: 17713971
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine.
    Jauregizar N; de la Fuente L; Lucero ML; Sologuren A; Leal N; Rodríguez M
    Clin Pharmacokinet; 2009; 48(8):543-54. PubMed ID: 19705924
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model.
    Deschamps C; Dubruc C; Mentre F; Rosenzweig P
    Clin Pharmacol Ther; 2000 Dec; 68(6):647-57. PubMed ID: 11180025
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients.
    Mould D; Chapelsky M; Aluri J; Swagzdis J; Samuels R; Granett J
    Clin Pharmacol Ther; 2001 Apr; 69(4):210-22. PubMed ID: 11309549
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacodynamic principles and the time course of immediate drug effects.
    Holford N
    Transl Clin Pharmacol; 2017 Dec; 25(4):157-161. PubMed ID: 32095468
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A pharmacokinetic/pharmacodynamic model for a platelet activating factor antagonist based on data arising from Phase I studies.
    Evans L; Aarons L; Brearley C
    J Pharm Pharmacol; 2005 Feb; 57(2):183-9. PubMed ID: 15720781
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 49.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 50.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 51.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.